“Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies”. 2018. SKIN The Journal of Cutaneous Medicine 2 (S1): S16. https://doi.org/10.25251/skin.2.supp.16.